Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H9O6P |
| Molecular Weight | 172.0737 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(CO)OP(O)(O)=O
InChI
InChIKey=DHCLVCXQIBBOPH-UHFFFAOYSA-N
InChI=1S/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
| Molecular Formula | C3H9O6P |
| Molecular Weight | 172.0737 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sources: https://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of
bile in human subjects with cholesterol gallstones in a short-term study
and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones
in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22383088 |
|||
Target ID: Protein phosphatase |
|||
Target ID: Glycerol-2-phosphatase |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1060200 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Glycophos Approved UseGlycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis. | 2018-08 |
|
| In vitro and in vivo acute response towards injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofiber hydrogel. | 2018-01-15 |
|
| Bone regeneration with osteogenic matrix cell sheet and tricalcium phosphate: An experimental study in sheep. | 2017-10-18 |
|
| The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway. | 2017 |
|
| Generation of osteogenic construct using periosteal-derived osteoblasts and polydioxanone/pluronic F127 scaffold with periosteal-derived CD146 positive endothelial-like cells. | 2013-04 |
|
| Taurine suppresses osteoblastic differentiation of aortic valve interstitial cells induced by beta-glycerophosphate disodium, dexamethasone and ascorbic acid via the ERK pathway. | 2012-10 |
|
| [Comparison study on injectable tissue engineered nucleus pulposus constructed by different cells and chitosan hydrogel]. | 2010-07 |
|
| Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation. | 2009-01 |
|
| Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells. | 2006-08 |
|
| Biomimetic apatite coatings on micro-arc oxidized titania. | 2004-08 |
|
| Bone regeneration by grafting of cultured human bone. | 2004-07-22 |
|
| Mechanism of action of beta-glycerophosphate on bone cell mineralization. | 1992-10 |
|
| Pericytes derived from the retinal microvasculature undergo calcification in vitro. | 1990-11 |
|
| Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis. | 1979 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/573222
6 g per day for 3 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:03:50 GMT 2025
by
admin
on
Mon Mar 31 18:03:50 GMT 2025
|
| Record UNII |
WWH06G87W6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1023106
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
241-228-2
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
WWH06G87W6
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
2526
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
m5792
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB01779
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
17270
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
C031463
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
58083
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
17181-54-3
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY | |||
|
Glycerol 2-phosphate
Created by
admin on Mon Mar 31 18:03:50 GMT 2025 , Edited by admin on Mon Mar 31 18:03:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |